Study of the Inflammatory Microenvironment in Atypical Meningiomas

Atypical Meningioma Clinical Trial

Official title:
Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas

Status Recruiting

Clinical Trial Summary

Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy. This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208). This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04761653
Study type	Observational
Source	Central Hospital, Nancy, France
Contact
Status	Recruiting
Phase
Start date	January 1, 2021
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04541082` - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Phase 1
Recruiting	`NCT02973256` - Oncological Care for Patients With Meningioma
Recruiting	`NCT03016091` - A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma	Phase 2
Recruiting	`NCT02847559` - Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma	Phase 2